Bausch + Lomb expects to begin the distribution of the intraocular dyes in all EU countries, with the exception of Italy, during the first half of 2023. Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets.
Bausch + Lomb Corp. and Alfa Instruments today announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes, Vitreocare, globally with the exception of Italy, where Alfa Instruments is based.
According to the companies, the agreement expands and enhances Bausch + Lomb's surgical portfolio offering with Alfa Instruments' differentiated intraocular dyes, which have been proven safe and effective in the European Union (EU).
"The addition of these clinically proven intraocular dyes to our already comprehensive surgical portfolio will help surgeons enhance the visibility of targeted eye tissues, as well as identify transparent layers of the eye during vitreoretinal, corneal and cataract surgery,"1-6 Joe Gordon, president, Global Consumer, Vision Care and Surgical, Bausch + Lomb., said in the news release. "Our exclusive collaboration with Alfa Instruments demonstrates our commitment to providing eye care professionals with innovative products that are designed to help them achieve the best possible surgical outcomes for their patients."
Under the agreement, Bausch + Lomb will assume responsibility for all distribution and commercial activities of Vitreocare intraocular dyes, which includes:
The companies pointed out that a common threat of the Vitreocare intraocular dyes is lutein, a natural blue light filter. Research has shown that lutein is a safe and effective dye agent, and its antioxidant properties can further protect the retina during eye surgery.1-6
Moreover, Single Lutein Blue and Double Lutein Blue are formulated with the new high purity (>99%) molecule Pure Benzyl-Brilliant Blue (PBB). PBB has been specifically designed in order to improve ILM binding affinity and to avoid diffusion into retinal layers, in order to avoid potential cytotoxicity on off-target tissues.7
"We are honored and delighted to collaborate with Bausch + Lomb, one of the best known and most respected eye care companies in the world, because it will expand access of our intraocular dyes through Bausch + Lomb's broad distribution network," Fabio David, CEO, Alfa Instruments, said in the news release. “We look forward to working together to help improve the vision needs of patients undergoing vitreoretinal, cataract or corneal surgery.”
Alfa Instruments' surgical dyes are currently CE marked and sold in the EU, the United Kingdom, and Switzerland. Bausch + Lomb expects to begin the distribution of the intraocular dyes in all EU countries, with the exception of Italy, during the first half of 2023. Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets.